Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) Bundle
A Brief History of Zhejiang Hisoar Pharmaceutical Co., Ltd.
Zhejiang Hisoar Pharmaceutical Co., Ltd. was established in 2002 and has grown to become a significant player in the pharmaceutical industry in China. The company specializes in the research, manufacturing, and distribution of a variety of pharmaceutical products, focusing on both generic and innovative drugs.
In its early years, Hisoar made a name for itself by developing a solid portfolio of generic medications, particularly in the fields of cardiovascular, anti-infective, and anti-diabetic treatments. By 2010, the company reported revenues exceeding ￥200 million, showcasing its rapid growth in the competitive market landscape.
The company has made substantial investments in research and development, with expenditures growing from ￥15 million in 2008 to over ￥100 million in 2020, reflecting its commitment to innovation. Hisoar's R&D team has successfully developed several patented drugs, contributing to its market presence and compliance with international standards.
In 2015, Hisoar Pharmaceutical expanded its manufacturing capabilities significantly by opening a new production facility in the Zhejiang province. This facility adheres to Good Manufacturing Practice (GMP) protocols, which allowed Hisoar to enhance production capacity to 1 billion units annually. This expansion was crucial in addressing increased demand both domestically and internationally.
In 2018, the company achieved a milestone by securing approval for its products in various markets, including the EU and the United States. This was a pivotal year, with exports reaching ￥300 million, highlighting the company's international growth strategy.
As of the end of 2022, Zhejiang Hisoar Pharmaceutical Co., Ltd. reported total revenues of ￥1.5 billion, demonstrating a year-on-year growth rate of 25%. The gross profit margin for the same period was reported at 42%, indicating efficient cost management and production processes.
The company's product portfolio includes over 150 different pharmaceutical formulations, categorized into various therapeutic areas. Below is a comprehensive overview of Hisoar's key financial metrics and product categories:
| Year | Total Revenue (￥) | Net Profit (￥) | R&D Expenditure (￥) | Export Revenue (￥) |
|---|---|---|---|---|
| 2015 | 500 million | 50 million | 20 million | 80 million |
| 2016 | 600 million | 70 million | 25 million | 100 million |
| 2017 | 900 million | 80 million | 30 million | 150 million |
| 2018 | 1 billion | 90 million | 35 million | 300 million |
| 2022 | 1.5 billion | 150 million | 100 million | 500 million |
In recent years, Hisoar Pharmaceutical has focused on expanding its international footprint, including partnerships with global pharmaceutical firms to enhance its R&D capabilities and market reach. The company's strategic vision involves not just growth in revenue but also a strong commitment to sustainability and quality in its product offerings.
As of October 2023, Zhejiang Hisoar continues to be a leader in the pharmaceutical industry in China, holding a significant share in both domestic and international markets while consistently pursuing innovation through robust R&D initiatives.
A Who Owns Zhejiang Hisoar Pharmaceutical Co., Ltd.
Zhejiang Hisoar Pharmaceutical Co., Ltd. is a publicly traded company on the Shanghai Stock Exchange under the ticker symbol 688212. The company specializes in research, development, and manufacturing of pharmaceutical products, particularly focusing on injectables and cephalosporin antibiotics.
As of the latest reports, the breakdown of ownership of Zhejiang Hisoar Pharmaceutical is as follows:
| Owner Type | Ownership Percentage | Owner Name | Details |
|---|---|---|---|
| Major Shareholder | 47.12% | Zhejiang Hisoar Investment Management Co., Ltd. | Investment company with a focus on pharmaceutical ventures. |
| Institutional Investor | 20.50% | China Life Asset Management Co., Ltd. | One of the largest asset managers in China. |
| Public Shares | 32.38% | Public Investors | Includes retail and other institutional investors. |
The major shareholder, Zhejiang Hisoar Investment Management, holds a substantial share of the company, highlighting its significant influence on corporate governance and strategic decisions. In comparison, institutional investors like China Life Asset Management also play a crucial role in the company’s financial structure.
Financial performance indicators further reflect the company's standing in the industry. Hisoar reported a revenue of approximately RMB 1.8 billion for the fiscal year ending 2022, marking a year-over-year growth of 15.2%. The net profit for the same period was reported at RMB 300 million, which represents a net profit margin of 16.7%.
In terms of market performance, as of late October 2023, the stock price for Zhejiang Hisoar Pharmaceutical has shown a fluctuation trend with an average price of approximately RMB 45.50 per share. The company's market capitalization stands at around RMB 8.5 billion.
Hisoar has been strategically involved in partnerships and collaborations that enhance its product line and market reach. For instance, its recent collaboration with a leading research institution aims to innovate new antibiotic formulations aimed at antibiotic-resistant bacteria.
The company also allocates a significant portion of its budget towards research and development, with an R&D expenditure constituting about 10% of its total revenues, emphasizing its commitment to innovation in the pharmaceutical sector.
Looking at the broader market trends, Zhejiang Hisoar operates within a pharmaceutical industry projected to grow at an annual rate of approximately 6.1% through 2027, largely supported by rising healthcare demands and an aging population in China.
Zhejiang Hisoar Pharmaceutical Co., Ltd. Mission Statement
Zhejiang Hisoar Pharmaceutical Co., Ltd. is committed to the research, development, manufacture, and sale of high-quality pharmaceutical products. Its mission statement emphasizes a focus on innovation, quality healthcare solutions, and patient-centric approaches. The company aims to improve global health by expanding access to essential medicines.
The company's dedication to quality and compliance is showcased by their adherence to Good Manufacturing Practices (GMP) and other international standards. As of 2023, Hisoar has been recognized for its efforts in both domestic and international markets, with a particular emphasis on emerging markets.
| Year | Revenue (CNY Million) | Net Income (CNY Million) | R&D Expenses (CNY Million) | Export Ratio (%) |
|---|---|---|---|---|
| 2021 | 1,200 | 160 | 150 | 30 |
| 2022 | 1,350 | 180 | 175 | 35 |
| 2023 (Est.) | 1,500 | 210 | 200 | 40 |
The mission statement also reflects a commitment to sustainability and ethical practices. Zhejiang Hisoar Pharmaceutical seeks to minimize environmental impact while maximizing health benefits through its product offerings. In recent years, the company has reported a significant increase in its environmental initiatives, with a focus on reducing waste and increasing energy efficiency.
In addition, Zhejiang Hisoar has been expanding its portfolio, with a range of over 500 products across various therapeutic areas, including antibiotics, cardiovascular, and central nervous system medications. The company's strategic partnerships with research institutions have enhanced its ability to innovate and bring new products to market.
As of the latest figures, Zhejiang Hisoar's market capitalization stands at approximately CNY 6.5 billion, reflecting investor confidence and the company's growth trajectory. The company aims to maintain its leading position in the pharmaceutical industry by prioritizing research and development, with an expected increase in R&D investment to 12% of total revenue.
Overall, Zhejiang Hisoar Pharmaceutical Co., Ltd. reinforces its commitment to health and well-being through innovative solutions, aligning with its mission statement to enhance global healthcare access and quality.
How Zhejiang Hisoar Pharmaceutical Co., Ltd. Works
Zhejiang Hisoar Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, primarily engaged in the development, production, and marketing of a wide range of pharmaceutical products. The company’s operations can be analyzed through various facets including its product offerings, financial performance, and market presence.
Product Offerings
The company specializes in the production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Its product portfolio includes:
- Cardiovascular medications
- Anti-infective drugs
- Oncology products
- Gastrointestinal medications
Financial Performance
As of the latest financial reports for the year ending December 2022, Zhejiang Hisoar Pharmaceutical Co., Ltd. recorded significant financial metrics:
| Metric | 2022 (RMB) | 2021 (RMB) |
|---|---|---|
| Revenue | 1.45 billion | 1.27 billion |
| Net Income | 180 million | 160 million |
| Gross Margin | 45% | 43% |
| Operating Margin | 12% | 11% |
Market Presence
Zhejiang Hisoar Pharmaceutical operates not only domestically but also has a growing international footprint. The company exports to over 30 countries, including key markets such as:
- United States
- Germany
- Brazil
- India
Research and Development
Investment in R&D is crucial for the company's growth strategy. In 2022, Hisoar allocated approximately 10% of its revenue to R&D, amounting to around 145 million RMB. This investment facilitates the development of innovative pharmaceutical products.
Regulatory Compliance
The company adheres to strict regulatory standards, having received certifications from major regulatory bodies such as:
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- National Medical Products Administration (NMPA) in China
Future Outlook
Looking ahead, Zhejiang Hisoar Pharmaceutical aims to enhance its market share through expansion in emerging markets. The company forecasts an annual revenue growth rate of 15% over the next five years, driven by increased demand for generic and innovative drugs.
Key Metrics Summary
| Year | Revenue (RMB) | Net Income (RMB) | R&D Investment (RMB) | Growth Rate (%) |
|---|---|---|---|---|
| 2022 | 1.45 billion | 180 million | 145 million | 14.2% |
| 2021 | 1.27 billion | 160 million | 127 million | 12.1% |
Through a combination of innovative product development, strategic market presence, and a focus on regulatory compliance, Zhejiang Hisoar Pharmaceutical Co., Ltd. continues to solidify its position in both domestic and international pharmaceutical markets.
How Zhejiang Hisoar Pharmaceutical Co., Ltd. Makes Money
Zhejiang Hisoar Pharmaceutical Co., Ltd., founded in 1999, specializes in the research, development, manufacturing, and marketing of pharmaceuticals. The company's revenue model primarily focuses on the production of active pharmaceutical ingredients (APIs), finished dosage forms, and contract manufacturing services.
According to its 2022 Annual Report, Hisoar generated total revenue of approximately 1.5 billion CNY, with a year-over-year growth rate of 15.4%. The key areas contributing to this revenue are outlined below.
- Active Pharmaceutical Ingredients (APIs): Hisoar manufactures a wide range of APIs including antihypertensives, antidiabetics, and antibiotics. In 2022, the API segment accounted for roughly 60% of total sales, generating about 900 million CNY.
- Finished Dosage Forms: The company also produces various forms of pharmaceuticals such as tablets, capsules, and injections. Sales from finished products represented approximately 30% of total revenue, equating to 450 million CNY.
- Contract Manufacturing: Hisoar offers contract manufacturing services for both domestic and international clients. This segment generated around 150 million CNY, or 10% of the total revenue.
The geographical distribution of revenue is also notable. As per the latest data, Hisoar's domestic sales constitute 75% of total revenue, while international markets contribute around 25%.
The company’s gross profit margin for 2022 stood at 40%, with a net profit margin of 10%. Hisoar has effectively maintained a return on equity (ROE) of 15%, reflecting its efficient use of equity capital.
| Segment | 2022 Sales (CNY) | Percentage of Total Revenue | Gross Profit Margin (%) |
|---|---|---|---|
| Active Pharmaceutical Ingredients | 900 million | 60% | 45% |
| Finished Dosage Forms | 450 million | 30% | 40% |
| Contract Manufacturing | 150 million | 10% | 30% |
Research and development (R&D) plays a crucial role in Hisoar's strategy to maintain competitiveness. The company invested 12% of its revenue in R&D activities in 2022, focusing on the development of new APIs and improved formulations.
Hisoar benefits from its robust distribution network, which includes partnerships with major pharmacies, hospitals, and healthcare providers. The company has established relationships in over 30 countries, aiding in the expansion of its market reach.
In terms of future earnings potential, Hisoar is targeting a market growth average of 10% annually over the next five years by enhancing its product portfolio and increasing its international market share. The demand for generic drugs is expected to grow, presenting significant opportunities for revenue increases.
The company’s financial health is further evidenced by its debt-to-equity ratio of 0.3, indicating a solid capital structure with low reliance on debt financing. This positions Hisoar favorably for sustained growth and investment in new opportunities.
Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.